Having trouble accessing articles? Reset your cache.

Anokion raises $40M series B, grabs back programs from spinout

Alongside raising $40 million in a series B round, autoimmune company Anokion said Wednesday it will acquire Kanyos Bio, a company it spun out and partnered with Astellas in 2015.

Versant Ventures, Novartis Venture Fund, Novo Ventures, select Swiss-based

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers